stockrow
Saturday 7 November 2026
Export CYVNY’s income statement to Excel — free account
Ceryvyn Therapeutics Ltd. - Unsponsored ADR
CYVNY Healthcare Biotechnology
Ceryvyn Therapeutics Ltd. - Unsponsored ADR’s revenue for fiscal 2025 (year ended June 2025) was $25,000.00, down 80.0% from fiscal 2024.
0.02
0.00
0.00%
Follow CYVNY
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to June
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | (15.8%) | 1 | 1 | 3 | +387.0% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | +100.0 pt | ||||||
| EBT | (6) | (7) | (21) | (25) | (17) | (50) | (99) | (148) | (230) | (170) | +44.9% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | (28,480.54) | (73,299.27) | (109,279.71) | (136,944.10) | (183,723.20) | (678,952.00) | (678,952.0) pt | ||||||
| Net income | (5) | 0 | (13) | (15) | — | — | — | — | — | — | +45.7% | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (0.03) | (0.20) | (0.43) | (0.51) | (0.33) | (1.13) | (2.11) | (2.58) | (2.76) | (1.06) | +48.8% | ||||||
| Cash flow | 0.00 | (0.20) | (0.51) | (0.58) | (0.17) | (1.14) | (1.62) | (2.18) | (2.02) | (1.04) | n/m | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | 0.00 | (0.20) | (0.51) | (0.58) | (0.16) | (1.12) | (1.62) | (2.18) | (2.02) | (1.04) | n/m | ||||||
| Book value | 0.00 | 1.80 | 0.97 | 0.75 | 1.37 | 3.38 | 1.09 | (0.11) | (0.95) | (1.31) | n/m | ||||||
| Shares, m | — | 23 | 29 | 29 | 33 | 40 | 44 | 55 | 80 | 153 | +26.6% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | 0.00 | 0.00 | 0.00 | 332.48 | 225.61 | 404.91 | 160.5 | ||||||
| P/B | — | — | — | — | 11.53 | 1.61 | 3.59 | 0.00 | 0.00 | 0.00 | 2.8 | ||||||
| EV/Sales | — | — | — | — | 0.00 | 0.00 | 0.00 | 317.97 | 347.87 | 1,161.82 | 304.6 | ||||||
| EV/FCF | — | — | — | — | (17.20) | (1.48) | (0.79) | (0.25) | (0.19) | (0.58) | (3.4) | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | (3) | (5) | (15) | (17) | (6) | (46) | (71) | (121) | (161) | (159) | +57.0% | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | +4.6% | ||||||
| Free cash flow | (3) | (5) | (15) | (17) | (5) | (45) | (71) | (121) | (161) | (159) | +57.0% | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | 11 | 41 | 28 | 21 | 44 | 135 | 48 | 80 | 124 | (201) | n/m | |||||
| Net debt | (11) | (40) | (24) | (15) | (43) | (118) | (45) | (3) | 28 | (48) | +18.2% | ||||||
| Shareholders’ equity | 11 | 42 | 28 | 22 | 45 | 135 | 48 | (6) | (76) | (201) | n/m | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | (17.23) | (75.13) | (53.49) | (49.47) | (29.36) | (48.28) | (93.54) | (179.62) | (153.25) | (132.57) | (115.3) pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | (517.79) | (144.96) | (1,803.34) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (18.24) | (17.96) | (35.67) | (59.78) | (33.54) | (50.42) | (101.29) | (676.68) | 539.40 | 117.59 | +135.8 pt | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | 8 | 9 | 18 | 24 | 34 | 4 | (12.9%) | |||||
| Revenue/emp, $m | — | — | — | — | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | (3.3%) | ||||||
Negative figures in brackets.
estimates
Fiscal years to Jun 2025 · fundamentals updated 26 Oct 2026
Ceryvyn Therapeutics Ltd. - Unsponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BCAX Bicara Therapeutics Inc. | $542.0M | — (loss-making) | — | — | n/m | −72.95% (below 0%: shrinking) | — | 0.00% | Compare |
| VALN Valneva SE Sponsored ADR | $536.5M | 59.3× | 19.4× | −17.29% (below 0%: shrinking) | n/m | −56.05% (below 0%: shrinking) | 15.29% | (76.67%) | Compare |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR | $524.8M | — (loss-making) | — (loss-making) | −7.53% (below 0%: shrinking) | n/m | −31.52% (below 0%: shrinking) | 0.00% | 0.00% | |
| ENTX Entera Bio Ltd. | $520.0M | — (loss-making) | — (loss-making) | +200.00% (above 0%: growing) | n/m | −108.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| FTH Faeth Therapeutics, Inc. | $514.8M | — (loss-making) | — | — | n/m | −262.66% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NGNE Neurogene Inc. | $513.3M | — (loss-making) | — (loss-making) | — | n/m | −22.97% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CLYM Climb Bio, Inc. | $509.5M | — (loss-making) | — | — | n/m | +3.73% (above 0%: growing) | — | 0.00% | Compare |
| YDES YD Bio Limited | $508.7M | — | — | — | — | — | — | — | Compare |
| SLBT SL SCIENCE HLDG | $504.7M | — | — | — | — | — | — | — | Compare |
| Median of peers | $514.1M | — | — | — | — | −64.50% | 7.65% | 0.00% |